Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: A randomized, placebo-controlled trial, ACTG 307

AIDS Research and Human Retroviruses

Volumn 20, Issue 9, 2004, Pages 916-926

  Frank, Ian ^a   Bosch, Ronald J ^b   Fiscus, Susan ^c   Valentine, Fred ^d   Flexner, Charles ^e   Segal, Yoninah ^b   Ruan, Ping ^b   Gulick, Roy ^f   Wood, Kenneth ^g   Estep, Scharla ^h   Fox, Lawrence ^h   Nevin, Thomas ⁱ   Stevens, Michael ^j   Eron Jr , Joseph J ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^j BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; HYDROXYUREA; LAMIVUDINE;

ADULT; ANEMIA; ANTIGENICITY; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MITOGENESIS; MONOTHERAPY; MULTICENTER STUDY; NEUTROPENIA; PANCREATITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; THROMBOCYTOPENIA;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; HYDROXYUREA; MALE; NUCLEIC ACID SYNTHESIS INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 5644227530     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2004.20.916     Document Type: Article

References (48)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, and Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
2. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, and Singh N: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
3. Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, Del Giudice P, Montagne N, Schapiro JM, and Dellamonica P: Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt Study. AIDS 2000;14:1333-1339.
4. Mocroft A, Phillips AN, Miller V, Gatell J, van Lunzen J, Parkin JM, Weber R, Roge B, Lazzarin A, Lundgren JD on behalf of the EuroSIDA Study Group: The use of and response to second-line protease inhibitor regimens: Results from the EuroSIDA study. AIDS 2001;15:201-209.
5. Gao W-Y, Johns D, and Mitsuya H: Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′- dideoxynucleosides. Mol Pharmacol 1994;46:767-772.
6. Malley SD, Grange JM, Hamedi-Sangsari F, and Vila JR: Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2′,3′-dideoxyinosine in infected resting human lymphocytes. Proc Natl Acad Sci USA 1994;91:11017-11021.
7. Lori F, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewicz J, and Gallo RC: Hydroxyurea as an inhibitor of human immunodeficiency virus type-1 replication. Science 1994;266:801-805.
8. Gao WY, Shirasaka T, Johns DG, Broder S, and Mitsuya H: Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 1993;91:2326-2333.
9. Meyerhans A, Vartanian JP, Hultgren C, Plikat U, Karlsson A, Wang L, Eriksson S, and Wain-Hobson S: Restriction and enhancement of human immunodeficiency virus type 1 replicaton by modulation of intracellular deoxynucleoside triphosphate pools. J Virol 1994;68:535-540.
10. Foli A, Lori F, Tinelli C, Minoli L, and Lisziewicz J: Hydroxyurea and didanosine as a more potent combination than hydroxyurea and zidovudine. Antiviral Ther 1997;2:33-40.
11. Lori F, Jessen H, Foli A, Lisziewicz J, and Matteo PS: Long-term suppression of HIV-1 by hydroxyurea and didanosine. JAMA 1997;277:1437-1438.
12. Hellinger JA, Iwane MK, Smith JJ, Fleishman AN, Torres RA, Schrader S, Perez G, Cohen CJ, Skowron G, Giordano MF, Accetta G, Cooper EC, and Frost KR: A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1. American Foundation for AIDS Research Community-Based Clinical Trials Network. J Infect Dis 2000;181:540-547.
13. Rutschmann OT, Opravil M, Iten A, Malinverni R, Vernazza PL, Bucher HC, Bernasconi E, Sudre P, Leduc B, Yerly S, Perrin LH, Hirschel B, and the Swiss HIV Cohort Study: A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS 1998;12:F71-77.
14. Moore RD, Keruly JC, and Chaisson RE: Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. AIDS 2001;15:617-620.
15. Havlir DV, Gilbert PB, Bennett K, Collier AC, Hirsch MS Tebas P, Adams EM, Wheat LJ, Goodwin D, Schnittman S, Holohan MK Richman DD, and the ACTG 5025 Study Team: Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. AIDS 2001;15:1379-1388.
16. Prentice R: Linear rank tests with right censored data. Biometrika 1978;65:167-180.
17. Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftu R, Cohen PT, and Grant RM: HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy. AIDS 1999;13:F35-43.
18. Biron F, Lucht F, Peyramond D, Fresard A, Vallet T, Nugier F, Grange J, Malley S, Hamedi-Sangsari F, and Vila J: Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. J Acquir Immune Defic Synd Hum Retrovirol 1995;10:36-40.
19. Clotet B, Ruiz L, Cabrera C, et al: Short-term anti-HIV activity of the combination of didanosine and hydroxyurea. Antiviral Ther 1996;1:189-193.
20. Montaner JSG, Zala C, Conway B, Raboud J, Patenaude P, Rae S, O'Shaughnessy MV, and Schechter MT: A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080. J Infect Dis 1997;175:801-806.
21. Kuritzkes DR, Marschner I, Johnson VA, Bassett R, Eron JJ, Fischl MA, Murphy RL, Fife K, Maenza J, Rosandich ME, Bell D, Wood K, Sommadossi J-P, and Pettinelli C: Lamivudine in combination with zidovudine, stavudine or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. AIDS 1999;13:685-694.
22. Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB Fiscus S, Rasheed S, Elbeik T, Reichman R, Japour A, Merigan TC, and Hirsch MS, for the AIDS Clinical Trials Group Study 175 Virology Study Team: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1091-1098.
23. + cells per cubic millimeter. N Engl J Med 1995;333:1662-1669.
24. Nokta M, Rossero R, Nichols J, Rosenbaum M, and Pollard RB: Effect of didanosine, stavudine, and hydroxyurea therapy on apoptosis in CD45RA+ and CD45RO+ T lymphocyte subpopulations. AIDS Res Hum Retroviruses 1999;15:255-264.
25. Murphy R, Katlama C, Autran B, et al.: The effects of hydroxyurea or placebo combined with efavirenz, didanosine, and stavudine in treatment naive and experienced patients: Preliminary 24 week results from the 3d study. XIII International AIDS Conference. Durban, South Africa, July 9-14, 2000.
26. Gu Z, Gao Q, Li X, Parniak MA, and Wainberg MA: Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 27prime;,3′- dideoxycytidine. J Virol 1992;66:7128-7135.
27. Eron J, Bosch R, Fetch L, Fiscus S, and Frank I, for the AACTG 307 Protocol Team: Antiretroviral activity of didanosine (ddI) in 3TC-experienced subjects in comparison to activity in subjects who were 3TC-naive. Antiviral Ther 2002;7:S56.
28. Panel on Clinical Practices for the Treatment of HIV Infection: DHHS Guidelines. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at http://www.aidsinfo.nih.gov. Accessed January 14, 2004.
29. Donehower R: An overview of the clinical experience with hydroxyurea. Semin Oncol 1992;19:11-19.
30. Charache S, Terrin ML, Moore RD, Dover GL, Barton FB, Eckert SV, McMahon RP, and Bonds DR, for the Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia: Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332:1317-1322.
31. Moore R, Wai-Ming E, Keruly J, and McArthur J: Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine, and hydroxyurea. AIDS 2000;14:273-278.
32. Rutschmann OT, Vernazza PL, Bucher HC, Opravil M, Ledergerber B, Telenti A, Malinverni R, Bernasconi E, Fagard C, Leduc D, Perrin L, and Hirschel B: Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study. AIDS 2000;14:2145-2151.
33. Biron F, Ponceau B, Bouhour D, Boibieux A, Verrier B, and Peyramond D: Long-term safety and antiretroviral activity of hydroxyurea and didanosine in HIV-infected patients. J Acquir Immune Defic Syndr 2000;25:329-336.
34. Barreiro P, Soriano V, Valencia E, Diaz B, and Gonzalez-Lahoz J: Low risk of pancreatitis in HIV-infected patients on hydroxyurea plus didanosine. AIDS 2001;15:2469-2470.
35. Lori F, Pollard R, Shalit P, Blick G, Patterson D, and Lisziewicz J: A low hydroxyurea dose (600 mg daily) is found optimal in a randomized, controlled trial (RIGHT 702). XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002. Abstract TuPeB4465.
36. Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein DA, and Merigan TC: Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Ann Intern Med 1994;121:263-268.
37. Mayers DL: Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs. Am J Med 1997;102:70-75.
38. Sharma PL and Crumpacker CS: Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation. J Virol 1997;71:8846-8851.
39. Miller V, Ait-Khaled M, Stone S, Griffin P, Mesogiti D, Cutrell A, Harrigan R, Staszewski S, Katlama C, Pearce G, and Tisdale M: HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS 2000;14:163-171.
40. De Antoni A, Foli A, Lisziewicz J, and Lori F: Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. J Infect Dis 1997;176:899-903.
41. Lisziewicz J, Rosenberg E, Lieberman J, Jessen H, Lopalco L, Siliciano R, Walker B, and Lori F: Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999;340:1683-1684.
42. Lori F and Lisziewicz J: Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. Clin Infect Dis 2000;30:S193-197.
43. Lori F, Jessen H, Lieberman J, Finzi D, Rosenberg E, Tinelli C, Walker B, Siliciano RF, and Lisziewicz J: Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J Infect Dis 1999;180:1827-1832.
44. Palmer S, Shafer RW, and Merigan TC: Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2- (phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates. Antimicrob Agents Chemother 1999;43:2046-2050.
45. Barreiro P, de Mendoza C, Camino N, García-Benayas T, Blanco F, Núñez M, González-Lahoz J, and Soriano V: Hydroxyurea plus didanosine as maintenance therapy for HIV-infected patients on long-term successful highly active antiretroviral therapy. HIV Clin Trials 2003;4:361-371.
46. Paton NI, Aboulhab J, and Karim F: Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1. Lancet 2002;359:1667-1668.
47. Margolis D, Heredia A, Gaywee J, Oldach D, Drusano G, and Redfield R: Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr 1999;21:362-370.
48. Margolis DM, Kewn S, Coull JJ, Ylisastigui L, Turner D, Wise H, Hossain MM, Lanier ER, Shaw LM, and Back D: The Addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. J Acquir Immune Defic Syndr 2002;31:45-49.